Article

PCSK7: a Novel Regulator of Apolipoprotein B and a Potential Target Against Non-Alcoholic Fatty Liver Disease

2023-03-24

Abstract excerpt

<title>Abstract</title> <p>Epidemiological evidence links the proprotein convertase subtilisin/kexin 7 (<italic>PCSK7</italic>) to triglyceride (TG) metabolism. <italic>PCSK7</italic>-SNPs gain-of-function and loss-of-function variants were associated with higher and lower levels of plasma apoB and TGs, respectively. Herein, we biochemically defined the <italic>in vivo</italic> role of <italic>PCSK7 </italic>in l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 598b7e4d-b880-55ed-a4fc-0063c96fd0da
DOI: 10.21203/rs.3.rs-2724841/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PCSK7: a Novel Regulator of Apolipoprotein B and a Potential Target Against Non-Alcoholic Fatty Liver DiseaseDOI 10.21203/rs.3.rs-2724841/v1Read

Proprotein convertase 7 (PCSK7) reduces apoA-V levels.Semantic proximity Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerSemantic proximity Read

PCSK9 affects expression of key surface proteins in human pancreatic beta cells through intra- and extracellular regulatory circuitsSemantic proximity Read

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patientsSemantic proximity Read

The PCSK9 decade.Semantic proximity Read

The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulationSemantic proximity Read

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read